Sodium colistimethate (cas 12705-41-8) loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis

Add time:08/27/2019    Source:sciencedirect.com

Lung impairment is the most life-threatening factor for cystic fibrosis patients. Indeed, Pseudomonas aeruginosa is the main pathogen in the pulmonary infection of these patients. In this work, we developed sodium colistimethate (cas 12705-41-8) loaded lipid nanoparticles, namely, solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), as a strategy to enhance the antimicrobial therapy against P. aeruginosa in cystic fibrosis patients. The nanoparticles obtained displayed a 200–400 nm size, high drug entrapment (79–94%) and a sustained drug release profile. Moreover, both SLN and NLC presented antimicrobial activity against clinically isolated P. aeruginosa. The integrity of the nanoparticles was not affected by nebulization through a mesh vibrating nebulizer. Moreover, lipid nanoparticles appeared to be less toxic than free sodium colistimethate in cell culture. Finally, an in vivo distribution experiment showed that nanoparticles spread homogenously through the lung and there was no migration of lipid nanoparticles to other organs, such as liver, spleen or kidneys.

We also recommend Trading Suppliers and Manufacturers of colistimethate (cas 12705-41-8). Pls Click Website Link as below: cas 12705-41-8 suppliers

Prev:Rapid communicationStability of colistimethate (cas 12705-41-8) sodium in a disposable elastomeric infusion device
Next:NotesPolymyxin B and colistimethate (cas 12705-41-8) are comparable as to efficacy and renal toxicity)